Immune checkpoint inhibitor rechallenge is effective and safe in HCCNovember 18, 2022Hepatocellular Carcinoma
Bevacizumab use is questionable in liver cirrhosis with locally advanced HCCNovember 18, 2022Hepatocellular Carcinoma
Advanced HCC: Antidrug antibody levels tied to outcomes in patients on atezolizumab/bevacizumabNovember 18, 2022Hepatocellular Carcinoma
Commentary: Multifocal Hepatocellular Carcinoma, November 2022October 31, 2022Hepatocellular Carcinoma
Alpha-fetoprotein: A real-time monitor in HCC treatment with atezolizumab and bevacizumabOctober 24, 2022Hepatocellular Carcinoma
Unrecognized liver cirrhosis common, associated with worse prognosis in HCCOctober 24, 2022Hepatocellular Carcinoma
Rigorous surveillance recommended after resection for HBV-related HCC in patients with metabolic syndromeOctober 24, 2022Hepatocellular Carcinoma
Blind spots require attention during abdominal ultrasonography-based HCC surveillanceOctober 24, 2022Hepatocellular Carcinoma
Microwave ablation: An alternative to resection in subcapsular HCC within the Milan criteriaOctober 24, 2022Hepatocellular Carcinoma
Antiplatelet therapy may decrease HCC incidence and improve post-treatment outcomesOctober 24, 2022Hepatocellular Carcinoma
Hepatectomy recommended for select patients with multiple HCCOctober 24, 2022Hepatocellular Carcinoma
Ramucirumab effective in patients with advanced HCC and AFP ≥400 ng/mL after non-sorafenib therapiesOctober 24, 2022Hepatocellular Carcinoma
Unresectable HCC: Atezolizumab plus bevacizumab proves its worth in the clinicOctober 24, 2022Hepatocellular Carcinoma
